News - details

10 December 2003

Isogenica signs an evaluation agreement with Johnson & Johnson Pharmaceuticals

Isogenica Ltd, Cambridge, UK today announced that it has signed an evaluation agreement with Johnson & Johnson Pharmaceuticals in which the utility of its CIS display technology for the discovery of biologically active peptides which are specific for targets provided by Johnson & Johnson will be explored.